ArticleCureus2025

Pathologic Complete Response Rates in Early-Stage Human Epidermal Growth Factor 2 (HER2)-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Anti-HER2 Therapy: A Real-World Experience.

Rania Mokfi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.